publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
HER3-DXd
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
Other/Multi
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: A multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)
Edoxaban
The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study
Edoxaban
Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: Patient characteristics from the prospective observational ETNA-AF-China registry
Edoxaban
Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial
Quizartinib
Safety and pharmacokinetics of quizartinib combination therapy with standard induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia: Results from two phase 1 trials in Japan and China.
T-DXd
Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action
T-DXd
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: A phase II study protocol (SHAMROCK study)
Other/Multi
HER2-mutant advanced and/or metastatic non-small-cell lung cancer: A US electronic health records database analysis of clinical characteristics, treatment practice patterns, and outcomes
T-DXd
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: A pooled analysis of two phase I studies